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Abstract
Human adenovirus 5 (AdHu5) vectors are robust vaccine platforms however the presence of naturally-acquired neutralizing
antibodies may reduce vector efficacy and potential for re-administration. This study evaluates immune responses and
protection following vaccination with a replication-incompetent porcine adenovirus 3 (PAV3) vector as an alternative
vaccine to AdHu5 using an avian influenza H5N1 disease model. Vaccine efficacy was evaluated in BALB/c mice following
vaccination with different doses of the PAV3 vector expressing an optimized A/Hanoi/30408/2005 H5N1 hemagglutinin
antigen (PAV3-HA) and compared with an AdHu5-HA control. PAV3-HA rapidly generated antibody responses, with
significant neutralizing antibody titers on day 21, and stronger cellular immune responses detected on day 8, compared to
AdHu5-HA. The PAV3-HA vaccine, administered 8 days before challenge, demonstrated improved survival and lower virus
load. Evaluation of long-term vaccine efficacy at 12 months post-vaccination showed better protection with the PAV3-HA
than with the AdHu5-HA vaccine. Importantly, as opposed to AdHu5, PAV3 vector was not significantly neutralized by
human antibodies pooled from over 10,000 individuals. Overall, PAV3-based vector is capable of mediating swift, strong
immune responses and offer a promising alternative to AdHu5.
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Introduction
Experimental adenovirus-based vaccine vectors are promising
alternatives to conventional vaccine platforms. In particular, human
adenovirus serotype 5 (AdHu5) vectors are well-characterized and are
being developed against several infectious disease models including
influenza, hepatitis C, dengue and viral hemorrhagic fever viruses
[1,2,3,4]. Several candidates haved e m o n s t r a t e du n i q u ep r o t e c t i v e
efficacy and can generate robust immune responses in both animal
models and clinical trials [4,5,6,7]. Pre-existing immunity against
AdHu5 is, however, frequent in the human population and has been
associated with undesirable clinical outcomes and the suspension of
clinical trials [8,9,10]. One promising alternative is the development
and evaluation of rare human, chimpanzee, or other mammalian
adenovirus vectors with low seroprevalence in humans. A chimeric
simian adenovirus 21 vector protected mice against lethal Ebolavirus
challenge and generated robust T-cell responses against the glycopro-
tein in nonhuman primates [11]. A bovine adenovirus 3 (BAV3)–based
vaccine previously demonstrated successful protection against avian
influenza A virus H5N1 challenge in mice and was able to escape pre-
existing neutralizing antibodies against AdHu5 [12]. Similarly, a
porcine adenovirus 3 (PAV3) vector was successful in several swine
vaccination studies against classical swine fever and pseudorabies virus
[13,14,15]. PAV3-based vaccines were able to evade pre-existing
immunity and provide long-term protection in pigs [14]. The antigenic
profile and reported in vivo efficacy as an animal vaccine makes the
PAV3 vector a promising alternative adenovirus vector for human
administration.
Due to their genetic diversity and the availability of several
significantly different isolates, avian influenza H5N1 viruses
provide a valuable and challenging disease model for evaluating
broad immune responses generated by potential adenovirus
vectors. The external hemagglutinin (HA) glycoprotein mediates
receptor binding, fusion, and can generate both strong antibody
and cell-mediated immune responses [16] which can be directly
assayed and provide useful comparison of adenovirus platforms.
Highly pathogenic avian influenza H5N1 viruses have spread
throughout domestic and aquatic bird populations in South East
Asia and the World Health Organization (WHO) has confirmed
500 clinical cases of H5N1 cross-transmission into humans.
Despite the limited incidence of human-to-human-transmission,
high mortality rates (.60%) and continuous evolution of the virus
represent a concern for future influenza pandemics [17,18]. The
emergence of pandemic swine-like H1N1 influenza A virus isolates
in early 2009 highlights the need to generate cross-protective and
lasting immune responses against diverging human and zoonotic
influenza viruses. In addition to evaluation of different adenovirus
platforms, the development of improved influenza vaccines would
also help in better preparation against emerging pandemic viruses
and could reduce the impact of infection on public health.
This study evaluates the protective efficacy following lethal
homologous challenge of a replication-incompetent porcine
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Hanoi/30408/2005 H5N1 (H5N1-H05) influenza A isolate
(PAV3-HA). The immunogenicity of HA and the success of
previous AdHu5 H5N1-HA vaccines [1,19] suggested that avian
influenza H5N1 may be a good comparative model to evaluate the
efficacy of a similar PAV3 vector.
Results
Seroprevalence of PAV3 in pooled human Ig
Previous studies showed that PAV3 does not exhibit cross-
reactivity with AdHu5 or BAV3 neutralizing antibodies [20,21].
Additionally, PAV3 was not neutralized by the lowest dilution of
1:4 from 50 randomly selected human sera [20] In order to further
address neutralization of PAV3 by an extended number of human
sera, human Ig made of pooled sera from 10,000–60,000
individuals was evaluated. AdHu5, used as a control, was
neutralized at the highest dilution of 1:160 (6.25610
23 mg/ml
human Ig). In contrast, neutralization of PAV3 was not detected at
1:20 (5.061022 mg/ml), the lowest dilution tested. Previous
studies showed little cross-reactivity between cell-mediated im-
mune responses against AdHu5 and PAV3 [22].
Vector construction and humoral immune responses
over time
An optimized expression cassette containing the codon-
optimized H5N1-HA was inserted by homologous recombination
into a replication-incompetent PAV3 vector containing deletions
in the E1/E3 genes (described in [23]). An AdHu5-HA vaccine
was also developed in parallel as a control to compare levels of
protection and immune responses. Expression of the PAV3-HA
and AdHu5-HA vaccines was evaluated in VRIBL E1, HEK 293,
and mouse AB12 cells (Figure 1a). BALB/c mice were also
vaccinated with 10
10 virus particles (vp) and in vivo expression of
PAV3-HA or AdHu5-HA in muscle tissue was detected 4 days
post-immunization (Figure 1b). A robust antibody response is
important for the prevention of influenza virus infection. The
ability of the PAV3-HA vaccine to generate humoral immune
responses following immunization was assayed through detection
of HA-specific antibodies by hemagglutination inhibition (HI) or
neutralizing antibody (NAB) titres. BALB/c mice were vaccinated
with 10
10 vp/mouse of PAV3-HA or AdHu5-HA and the
development of HI and NAB antibody responses was monitored
from serum collected at days 8, 10, 14, and 21 post-immunization.
All samples were treated with receptor-destroying enzyme (RDE),
followed by complement inactivation the next day. An HI assay
was performed using serial dilutions of the treated serum
combined with H5N1-H05 virus and horse red blood cells to
detect inhibition of cell agglutination by serum antibody. The
reciprocal of the highest dilution which did not agglutinate red
blood cells was scored as the HI antibody titre. HI titres of 2060,
120669, 213692, 5336184 were detected for PAV3-HA and
27611, 67623, 213692, 4266184 for AdHu5-HA, respectively,
with no statistical difference between the two vaccines (Figure 2a).
Figure 1. Comparative detection of H5N1-H05 HA protein expressed by AdHu5-HA and PAV3-HA. Transgene expression was detected
by Western Blot using polyclonal anti-H5N1 mouse sera and a goat anti-mouse-HRP secondary antibody. (A) M=Marker, Lane 1=expression of
AdHu5-HA in HEK 293 cells, Lane 2=expression of PAV3-HA in VRIBLE1 cells, Lanes 3 and 4 expression of AdHu5-HA and PAV3-HA in mouse syngenic
AB12 cells, (2) negative control, untransfected cell lysate. (B) In vivo expression in mouse muscle tissues 4 days following vaccination. 75 mg of muscle
tissue was loaded in each lane to compare protein expression. M=Marker, Lanes 1–6=PAV3-HA, Lanes 8–13=AdHu5-HA, (2)=unvaccinated muscle
tissue.
doi:10.1371/journal.pone.0015301.g001
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H05 infection was also evaluated as a measure of the humoral
response. Serial dilutions of treated serum were incubated with
100 pfu/well of H5N1-H05 virus and cells were monitored for the
presence or absence of cytopathic effects (CPE) using a light
microscope. The highest serum dilution which did not exhibit
CPE was scored as positive for neutralizing antibody and titres
were reported as the reciprocal of the dilution. NAB titres of 060,
7612, 7612 and 90650 or 060, 7612, 10610 and 4060
reciprocal dilutions were observed with the PAV3-HA or AdHu5-
HA vaccines at 8, 10, 14, and 21 days, respectively (Figure 2b).
The increased neutralizing antibody response following PAV3-HA
vaccination was statistically significant at day 21 (p=0.045)
relative to AdHu5-HA.
In order to assess antibody titres immediately before challenge,
mice were vaccinated with different doses of each vaccine and
serum was obtained 25-days post-immunization. HI reciprocal
titres of 9866326, 10936293, and 1280 for the PAV3-HA
vaccine or 10666330, 10666330, and 11736261 with AdHu5-
HA were detected for 10
8,1 0
9 or 10
10 vp/mouse doses
respectively (Figure 2c). Both vaccines had similar HI antibody
titres at all doses, with no significant differences detected between
Figure 2. Hemagglutination inhibition (HI) and neutralizing antibody (NAB) assays for PAV3-HA and AdHu5-HA. Serum was obtained
from groups of PAV3-HA ( ) or AdHu5-HA ( ) vaccinated BALB/c mice and treated overnight at receptor-destroying enzyme (RDE), followed by
complement inactivation the following day. (A) Kinetics of the HI antibody response. Serum was obtained from groups of 4 BALB/c mice on days 8,
10, 14, and 21 post-vaccination with 10
10 vp/mouse of PAV3-HA or AdHu5-HA. Four agglutinating doses of H5N1-H05 virus were added to serial
dilutions of serum and samples were incubated with horse red blood cells. HI antibody titre was determined as the reciprocal of the highest serum
dilution which did not cause red blood cell agglutination. (B) Kinetics of the NAB response. Serum from obtained on 8, 10, 14, and 21 days post-
vaccination with 10
10 vp/mouse of PAV3-HA or AdHu5-HA. Serial dilutions of was also incubated with 100 pfu of H5N1-H05 virus, added to MDCK
cells and monitored for the presence of cytopathic effects (CPE) over 48 hours. The NAB titre was scored as the highest serum dilution with the
absence of CPE. (C) HI titre against H5N1-H05. Serum was obtained 25 days post-immunization from groups of 5–10 BALB/c mice were vaccinated
with 10
8,1 0
9, and 10
10 vp/mouse of AdHu5-HA or PAV3-HA and the HI titre was assayed. (D) NAB titres against H5N1-H05. Serum from 25 days post-
immunization was also monitored for NAB titre. The data represent average values and standard deviations from 3 to 5 experiments performed with
2 independent vector preparations of each vaccine (* represents p,0.05).
doi:10.1371/journal.pone.0015301.g002
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reference HI antibody titre of 40 is recommended for influenza
vaccine candidates as the minimum level to confer fifty percent
protection in humans [24,25]. Both vaccines met this requirement
at all doses prior to challenge. Serum samples had an average
NAB titre of 65620, 75614, or 106646 reciprocal dilution at 10
8,
10
9 or 10
10 PAV3-HA vp/mouse respectively (Figure 2d). The
AdHu5-HA vaccine generated NAB titres of 65620, 55620 or
133646 at 10
8,1 0
9 or 10
10 vp/mouse, respectively.
Cellular immune responses over time
Although a strong antibody response is important for immediate
and long-term protection against influenza viruses, the induction
of early cellular immune responses following vaccination may
enhance clearance of virus-infected cells following H5N1 influenza
virus infection. T-cell responses were assayed using an enzyme-
linked immunosorbent spot (ELISPOT) assay to detect secretion of
interferon gamma (IFNc) by activated lymphocytes. Splenocytes
were obtained from mice vaccinated at days 8, 10, 14, and 21 with
10
10 vp/mouse of PAV3-HA or AdHu5-HA and the cells were
restimulated with pools of overlapping peptides corresponding to
the entire H05-HA protein. The peptide corresponding to the
immunodominant H5N1-H05 HA (IYSTVASSL, conserved
influenza A virus) epitope was evaluated alongside an unrelated
control peptide (TYQRTRALV, A/PuertoRico/8/34 H1N1
nucleoprotein).
In mice vaccinated with PAV3-HA, 13,59862066, 14,4426
2541, 69546392, or 20566633 spot-forming cells (sfc) per million
splenocytes were detected at days 8, 10, 14, or 21 respectively
(Figure 3a). Immunization with the AdHu5-HA vaccine generated
1,9656341, 12,85861749, 7332693, and 19026372 sfc/million,
respectively. The number of sfc/million splenocytes detected at
day 8 was statistically significant between PAV3-HA and AdHu5-
HA vaccines (p,0.005). The H05-HA immunodominant epitope
also stimulated the strongest T-cell responses on day 8 for the
PAV3-HA vaccine compared to AdHu5-HA. PAV3-HA vacci-
nated mice generated an average of 8126138 sfc/million at day 8
whereas 2206133 sfc/million were detected from AdHu5-HA
mice at the same time point (Figure 3b, p=0.048). At day 10,
average responses following stimulation with the H05-HA
immunodominant epitope were 1,2166178 or 1,364636 sfc/
million from PAV3-HA or AdHu5-HA immunized mice respec-
tively (p=0.258). T-cell responses of 770674 and 453684 were
detected from PAV3-HA or 791658 and 590684 from AdHu5-
HA at days 14 and 21 post-immunization, respectively. Re-
stimulation of splenocytes from PAV3-HA or AdHu5-HA
immunized mice by the NP control peptide repeatedly generated
less than 65 sfc/million.
Cellular responses following vaccination with PAV3-HA were
further characterized by detecting the relative frequency of
peptide-specific CD8
+ T cells expressing IFN-c by flow cytometry.
Splenocytes were harvested ten days post-immunization and re-
stimulated in vitro with the H05-HA immunodominant peptide and
unrelated NP or ZGP (TELRTFSI, Zaire Ebolavirus glycoprotein)
control peptides. Cells were stained with anti-mouse CD8-FITC
(fluorescein isothiocyanate) and an anti-mouse IFNc-PE (phyco-
erythrin). The frequency of IFNc positive CD8
+ T-cells was
3.460.3 and 2.860.3 percent for PAV3-HA or AdHu5-HA,
respectively (Figure 3c). Cells stimulated with control peptide NP
or ZGP showed frequencies of CD8
+ IFNc positive T-cells equal
to 0.360.05 or 0.660.05 percent, respectively. These results
suggest that the PAV3-based vaccine can stimulate a robust
immune response in mice faster than AdHu5HA and comparable
in strength.
Protective efficacy of PAV3-HA following lethal challenge
The early detection of the T-cell response at day 8 post-
vaccination with the PAV3-HA vaccine suggest that it may be a
good candidate for immediate administration just prior or following
a suspected exposure to H5N1 virus. The success of rapid
vaccination regimen was evaluated in two parts: first, overall
survival and second, total viral load in lung tissue, as determined by
TCID50 assay. BALB/c mice were challenged with a lethal dose of
H5N1-H05 virus at 5, 8 and 10 days post-vaccination and lungs
were harvested at day 3 post-infection. Although mice challenged 5
days post-vaccination did not survive lethal challenge (Figure 4a),
animals challenged 8 days post-vaccination experienced significant-
ly greater survival with the PAV3-HA (66% survival) vaccine than
for AdHu5-HA (11% survival) and had less signs of disease and
weight loss (Figure 4b, p=0.038). Both vaccines were fully
protective with minimal signs of disease when administered 10
days prior to challenge (Figure 4c). Lung viral titres were
significantly lower at all time points with both vaccines compared
to unvaccinated control animals (Figure 4d). Following vaccina-
tion with PAV3-HA, virus titers were 3.57610
666.26610
6,
1.40610
664.87610
6, and 4.82610
666.57610
6 TCID50/g, for
days 5, 8, and 10 respectively and 1.64610
768.60610
6,
1.03610
766.9610
6, and 3.52610
665.76610
6 logTCID50/g for
AdHu5-HA. The PAV3-HA vaccine was associated with signifi-
cantly lower viral load in animals vaccinated at both days 5 and 8
compared to AdHu5-HA (p=0.032 and p=0.048, respectively).
Both vaccines were similar on day 10 (p=0.72).
Survival was also assessed in groups of 10 BALB/c mice
vaccinated with 10
8,1 0
9,o r1 0
10 virus particles of recombinant
adenovirus PAV3-HA or AdHu5-HA by intramuscular (I.M.)
administration, challenged 28 days later with lethal homologous
H5N1-H05 virus. Protection against clinical signs of disease with
minimal weight loss and full survival was observed at the 10
10 vp/
mouse dose for both Ad-based vaccines (Figure 5). Complete
survival was also observed for both vaccines at a dose of 10
9 vp/
mouse, with the PAV3-HA vaccinated mice either asymptomatic
or having milder signs of disease (14% weight loss) compared to
AdHu5-HA (21% weight loss). Another desirable characteristic
that influenza vaccines should provide is long-term protection.
Therefore, long term immunity was evaluated in mice challenged
12 months after vaccination in order to determine whether
protective immune responses could be maintained. PAV3-HA
afforded full protection in mice challenged with 100 LD50 of
H5N1-H05 virus 12 months post-immunization whereas 50% of
mice vaccinated with AdHu5-HA succumbed (Figure 6a). Higher
HI antibody titers for PAV3-HA compared to AdHu5-HA
(186665 and 60623, respectively (p=0.006)) may have translated
directly to the improved survival observed with the PAV3-HA
vaccine. NAB titers were 23615 and 10611 for AdHu5-HA
(Figure 6b). An ELISA assay was also performed to detect total
IgG antibody titres against the H5N1-HA antigen. Serum was
obtained from mice 25 days and 1 year post-vaccination, and
unvaccinated control mice (Figure 6c). Total antibody titers were
significantly lower for both vaccines after 1 year. On average,
higher levels of IgG antibodies were detected for the PAV3-HA
vaccine, however the difference was not statistically significant
compared to AdHu5-HA (p=0.241).
Discussion
Currently, replication-deficient human adenovirus serotype 5
(AdHu5) vaccines are being evaluated against several pathogens.
Several candidates have been shown to induce protective immune
responses against emerging or re-emerging infectious pathogens
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Complete protection and long-term memory responses have also
been reported in different animal models [7,26,28]; however, the
final development of AdHu5-based vector to approved human
vaccines has been hampered by the presence of natural pre-
existing immunity to AdHu5 which is present in a large fraction of
the human population. Neutralizing antibody to porcine adeno-
virus 3 (PAV3) was not detected from pooled immune globulin
representing 10 to 60 thousand human sera suggesting that pre-
existing immunity to PAV3-based vaccines is not likely to be of
concern for human applications. In addition, the documented
compatibility of porcine and human tissues could translate into
PAV3-based vaccines being efficacious while of low toxicity in
humans [23]. The further development of a new adenovirus
serotype also increases the spectrum of possible applications such
as sequential vaccination with other adenovirus vectors (e.g.
prime/boost or a second Ad-based vaccination against a different
agent) [20,29].
The present study compares in parallel the immune responses
and protection generated by a PAV3-based vector and a similar
AdHu5-based vector using an avian influenza H5N1 disease
model of infection. PAV3-based vector expressing the H5N1 HA
antigen was able to generate quick and robust immune responses
against H5N1. This finding was supported by the rapid induction
of improved immediate protection by the PAV3-HA vaccine
compared to AdHu5-HA. Interestingly, both vaccines shared
similar in vivo expression, suggesting that the increase in vaccine
efficacy observed with PAV3-HA may be due to specific
Figure 3. T-cell responses detected by ELISPOT-IFNc and flow cytometry. Groups of 4 BALB/c mice were vaccinated with 10
10 vp/mouse of
either PAV3-HA ( ) or AdHu5-HA ( ). Mouse spleens were harvested 8, 10, 14, and 21 days post-immunization and positive T-cell responses
following peptide restimulation were determined through IFNc secretion, as indicated by spot formation on the membrane. (A) Pooled T-cell
responses. Cells were restimulated with a peptide library of overlapping 15mers spanning the entire H05-HA protein. Bars represent the total number
of spot-forming cells/million mononuclear cells for all peptide pools combined. The data represent average values and standard deviations from 4
experiments performed with 3 independent vector preparations of each vaccine (* represents p,0.005). (B) T-cell responses following stimulation
with immunodominant peptide. Splenocytes were restimulated with individual 9mer or 8mer peptides representing the immunodominant epitope of
H05-HA (IYS) or control peptides (PR8-NP TYQ (), ZGP). Positive responses for IFNc secretion were detected by ELISPOT. Bars represent the total
number of spot-forming cells/10
6 mononuclear cells. The data represent average values and standard deviations from 4 experiments performed with
3 independent vector preparations of each vaccine (** represents p,0.05). C) Flow cytometric analysis representing the percentage of CD8
+IFNc
secreting T-lymphocytes day ten post-immunization. The data represent average values and standard deviations from 3 experiments performed with
one vector preparation of each vaccine.
doi:10.1371/journal.pone.0015301.g003
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expression of the antigen. A recent study suggests that PAV3-
HA may activate different innate immune pathways to AdHu5-
HA [30]. Additionally, the PAV3-HA offered improved long-term
protection against lethal H5N1 virus challenge with higher levels
of detectable antibodies by HI assay. Although full short-term (28
day) survival was observed following vaccination with PAV3-HA
or AdHu5-HA at the 10
9 vp/mouse dose, greater weight loss was
observed with the AdHu5-HA vaccine. Comparing HI and NAB
antibody titres with observed clinical outcome, this suggests that
there may have been incomplete neutralization of the virus
following vaccination with AdHu5-HA, perhaps explaining why
there were differences in the levels of protection observed
following challenge 1-year post-vaccination. It has been shown
that levels of neutralizing antibodies in serum decrease over time
following H5N1 infection [31]. Following vaccination, the exact
levels of neutralizing antibodies correlating with full protection
from infection with homologous virus is still uncertain. In
comparison with total IgG antibody levels, neutralizing antibody
titres correlated better with early and long-term protection, similar
to previously described reports [19,32,33].
Together the data suggests that PAV3 vector is an additional
option to AdHu5 vector and could have several important
applications including rapid or post-exposure protection against
emerging influenza viruses or other infectious agents. A similar
study described a BAV3-HA vaccine sharing comparable
protective efficacy to the AdHu5-HA against an H5N1 virus.
Two doses of the BAV3 vector generated similar humoral and cell-
mediated immune responses and was able to evade pre-existing
neutralizing antibodies against AdHu5 [12]. Overall protective
efficacy offered by PAV3-HA was similar to AdHu5-HA one
month post-immunization and the immune response kinetics was
also generally comparable at later time points. Although not
explored in the current study, previous studies have evaluated the
impact of pre-existing immunity to PAV3 and the potential reuse
of PAV3-based vectors against different pathogens. Groups of
outbred pigs with high PAV3 neutralizing antibody titres were
vaccinated with a PAV3-based vaccine and vector re-administra-
tion did not result in hepatotoxicity or reduced transgene
expression [14]. Doses of 10
13 particles/kg AdHu5 vector can
also bypass pre-existing immunity, however, several pathologies
including liver damage indicated by elevated transaminase, low
platelets count, and lymphocytopenia were observed in nonhuman
primates administered similar doses [9,10,34,35].
Even though conventional vaccines have been relatively
successful against influenza A infection, the ability of adenoviral
vectors to rapidly generate a strong immune response may be
useful to specific applications such as rapid immunization of health
care workers in anticipation of a probable exposure to an
emerging virulent pandemic virus such as H1N1-1918. In addition
to strong antibody responses against the H5N1-H05 virus, both
survival and cellular responses suggest that induction of an earlier
T-cell response by the PAV3-may complement the developing
antibody response to improve protection against H5N1 challenge
and contribute directly towards lower viral load. Although the
influenza glycoproteins have high antigenic variation, the
generation of faster T-cell responses by a PAV3 vector against
well-conserved influenza antigens may supplement a mismatched
antibody response and may improve protection against a wider
range of influenza viruses.
Previous studies have shown that PAV3 vectors can transduce
several human cell lines resulting in full transgene expression and
adenoviral coat proteins [20,21]. An additional safety feature is
that wild-type PAV3 does not replicate in human cells [21],
Figure 5. Groups of 10 BALB/c mice were vaccinated with PAV3-HA at a dose of 10
8 (e), 10
9 (,), and 10
10 (n) vp/mouse, AdHu5-HA
10
8 (¤), 10
9 (.), and 10
10 (m), or PBS Control (N). Twenty-eight days post-vaccination, the mice were challenged with 100LD50 of H5N1-H05
virus and monitored for (i) survival and (ii) weight loss and clinical signs of disease.
doi:10.1371/journal.pone.0015301.g005
Figure 4. Protection following vaccination with PAV3-HA or AdHu5-HA vaccine. (A–C) Groups of 9 BALB/c mice were vaccinated with
10
10 vp/mouse of PAV3-HA (n), AdHu5-HA (m), or PBS Control (N) and challenged with 100LD50 of H5N1-H05 on days 5, 8, and 10 post-vaccination.
(A) Protection afforded 5-days post-vaccination. (i) survival and (ii) weight loss. (B) Protection afforded 8-days post-vaccination. (i) survival and (ii)
weight loss. (C) Protection afforded 10-days post-vaccination. (i) survival and (ii) weight loss. The data represent average values and standard
deviations from 2 experiments performed with 2 independent vector preparations of each vaccine (D) Lung viral titres 3 days after lethal challenge.
Groups of 6 BALB/c were vaccinated with 10
10 vp/mouse of PAV3-HA () or AdHu5-HA (), or no vaccine (Control, ()) and challenged with 100LD50 of
H5N1-H05 on days 5, 8, and 10 post-vaccination. Lungs were harvested from the mice on day 3 post-challenge. Virus titre was determined by TCID50
assay using serial dilution of lung homogenates on MDCK cells and monitoring for the presence of CPE over 48 hours. The TCID50 titre was calculated
by the Reed & Muench method [39] and normalized/gram of lung tissue. Data is presented as log10 TCID50/g of lung tissue. The data represent
average values and standard deviations from one experiment performed with one vector preparation of each vaccine (* and ** represents p,0.05).
doi:10.1371/journal.pone.0015301.g004
A Porcine Adenovirus Vaccine Vector against H5N1
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15301suggesting that a replication-competent PAV3 vector which would
be easy to produce at high titres could also be a promising vaccine
candidate. Nevertheless, performance of this new vaccine vector
will need to be addressed in other animal species, including
nonhuman primates, before its real utility as a human vaccine can
be predicted more accurately. Overall, this study supports a
complementary role for cellular immunity during early H5N1
infection and the further development of porcine adenoviruses as
human vaccine candidates.
Materials and Methods
Ethics Statement
All animal procedures and scoring sheets were first approved by
the Animal Care Committee (Animal Use Document ID# H-08-
010) at the Canadian Science Centre for Human and Animal
Health, according to the guidelines set by the Canadian Council
on Animal Care.
Cells and viruses
Human embryonic kidney (HEK) 293 cells, Madin-Darby
canine kidney cells (MDCK), and mouse AB12 cells were
maintained in Dulbecco’s modified eagle’s medium (DMEM),
supplemented with 10% fetal bovine serum (FBS), L-glutamate,
sodium pyruvate (NaPyr), and antibiotics. Fetal porcine retina cells
(VR1BL E1), expressing human adenovirus 5 (AdHu5) E1a and
porcine adenovirus 3 (PAV3) E1b large genes, were maintained in
minimum essential medium (MEM) alpha, supplemented with
10% FBS, L-glutamate, NaPyr, non-essential amino acids, HEPES
buffered saline, penicillin/streptomycin, and 50 mg/ml Hygro-
Figure 6. Long-term protection in BALB/c mice. Long-term protection was evaluated in groups of six BALB/c mice vaccinated with PAV3-HA 10
9
(,) vp/mouse, AdHu5-HA 10
9 (.) vp/mouse, and PBS Control (N). (A) Mice were challenged 12 months following vaccination with 100LD50 of H5N1-
H05 virus and monitored for (i) survival and (ii) weight loss and clinical signs of disease. (B) Long-term antibody responses. Serum was collected 12
months post-vaccination from mice immunized with PAV3-HA ( ) or AdHu5-HA ( ). HI and NAB responses were evaluated. The data represent
average values and standard deviations from one experiment performed with one vector preparation of each vaccine (* represents p=0.006). (C)
ELISA detecting total IgG antibody titres against the H5 HA antigen. Endpoint titers were assessed for PAV3-HA ( ) or AdHu5-HA ( ) 25 days and 1
year post-vaccination.
doi:10.1371/journal.pone.0015301.g006
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Hanoi/30408/2005 (H5N1) was generously provided by Q. Mai
Le and T. Hien Nguyen, National Institute of Hygiene and
Epidemiology, Hanoi, Vietnam. Virus was propagated on MDCK
cells cultured with virus diluent (MEM, 0.3% bovine serum
albumin, and antibiotics) containing 3.0 mg/ml TPCK-treated
trypsin (TPCK-trypsin) and titered by plaque assay. All infectious
recombinant adenovirus constructs were propagated on HEK 293
or VR1BL E1 cells and purified by a cesium chloride density
gradient.
Vectors and construction of transfer plasmids
The full complementary DNA (cDNA) sequence from the A/
Hanoi/30408/2005 H5N1 hemagglutinin (H05-HA) gene was
obtained, codon optimized, and synthesized from overlapping
oligonucleotide primers, as previously described [36]. The H05-
HA gene was first cloned into the pCAGa plasmid, containing a
chicken-b-actin (CAG) promoter, to generate the pCAGa-HA
construct. The pCAGa-HA expression cassette was then excised
and inserted into two shuttle vector systems: pShuttle2 (Clontech)
and pPAV227 (VIDO, University of Saskatchewan). Insertion of
the expression cassette replaced the existing pShuttle2 cytomeg-
alovirus (CMV) promoter with the CAG promoter, resulting in the
pShuttle2-HA construct. Transfer plasmid pPAV227 was also
modified to include the SV40 polyadenylation signal from
pShuttle2, generating pPAV227- HA-PolyA.
The transgene cassettes from pShuttle2-HA and pPAV227-HA-
PolyA were cloned into replication-deficient DE1DE3 adenoviral
vectors: pAdenoX (AdHu5, Clontech) or pFPAV227 (PAV3,
VIDO, University of Saskatchewan). pAdenoX-HA was generated
through digestion of both pShuttle2-HA and pAdenoX by homing
endonucleases I-CeuI/PI-SceI and ligation of cohesive ends using
T4 DNA ligase (Invitrogen). pFPAV227-HA was generated
through homologous recombination in Escherichia coli strain
BJ5183 (recBC, sbcBC) [37] of linearized pPAV227-HA-PolyA
(Eco47III/TthIII1) and pFPAV227 (PacI).
Production of PAV3-HA and AdHu5-HA vaccine vectors
To obtain AdHu5-HA vaccine, HEK 293 cells were transfected
with 10 mg of linearized pAdenoX-HA DNA in calcium phosphate
(BD Biosciences) solution and cells were cultured until the
appearance of cytopathic effects (CPE). Similarly, VR1BL E1
cells were transfected with 10 ug of linearized pFPAV227-HA
DNA combined with Lipofectin (Invitrogen) and cells were
cultured until CPE were apparent. Amplified adenoviruses
containing cell lysates were harvested, freeze-thawed three times,
and purified by CsCl gradients. The integrity of the H05-HA
transgene cassette was confirmed through EcoRI restriction digests
and by sequencing (DNA Core, National Microbiology Labora-
tory) with multiple primer sets. Total virus particles (vp) was
determined by OD260 and total infectious particles was
determined using anti-hexon antibodies against AdHu5 (AdenoX
Rapid Titer kit, Clontech) or against PAV3 (VIDO, University of
Saskatchewan). Four independent vector preparations were used
for each vaccine. Total infectious particles and total viral particles
were determined for both adenovirus vaccines, with ratios of
1:285, 1:333, 1:250, and 1:300 for PAV3-HA and 1:150, 1:250,
1:220, and 1:250 for AdHu5-HA.
Expression of PAV3-HA and AdHu5-HA vaccines
Protein expression of H05-HA by both vectors was confirmed in
HEK 293, VRIBL E1, and AB12 cells using standard Western
blotting techniques. To evaluate in vivo expression, groups of
6 BALB/c mice were vaccinated with 10
10 vp of PAV3-HA or
AdHu5-HA and muscle tissue was harvested 4 days following
immunization. Muscle tissues were homogenized and normalized
per gram of muscle tissue in radioimmunoprecipitation (RIPA)
buffer. Expression of each vaccine was detected from 75 mgo f
loaded muscle tissue.
Immunization and viral challenge
Groups of 10 BALB/c (Charles River Canada) were vaccinated
with 10
8,1 0
9,o r1 0
10 vp of recombinant adenovirus PAV3-HA or
AdHu5-HA by intramuscular (I.M.) administration. Each vaccine
was diluted in 100 ml and 50 ml was administered in each of the
right and left hind limbs. All mice were anesthetized and
challenged after 28 days through intranasal inoculation with 100
times the dose of A/Hanoi/30408/2005 virus required to obtain
50% survival (100 Lethal Dose 50 or 100LD50) in 50 ml virus
diluent. The LD50 for the H5N1-H05 virus was 1.05 plaque
forming units (pfu), therefore 100LD50 was 105 pfu. Mice were
monitored for 15 to 20 days following challenge and signs of
disease including weight loss, labored breathing, ruffled fur, and
death were observed according to an approved scoring chart. All
animal procedures were approved by the Institutional Animal
Care Committee at the National Microbiology Laboratory (NML)
at the Public Health Agency of Canada (PHAC), according to the
guidelines of the Canadian Council on Animal Care. All infectious
work was performed in the high biocontainment laboratory at
NML/PHAC.
Enzyme-linked immunosorbent spot assay
Groups of 4 BALB/c mice were vaccinated with 10
10 vp of
PAV3-HA or AdHu5-HA vaccines. The day before each
experiment, ELISPOT-IFNc (BD Biosciences) plates were coated
with purified mouse IFNc and incubated at 4uC, overnight. As
well, overlapping 15mer peptides (Mimitopes, Australia) spanning
the entire H05-HA protein were resuspended overnight in
dimethyl sulfoxide (DMSO) and allocated in pools by matrix
format. Spleens were harvested on days 8, 10, 14, and 21 post-
immunization and splenocytes were plated at 5610
5 cells/well in
RPMI 1640 (supplemented with 10% FBS, L-glutamine, NaPyr,
HEPES, non-essential amino acids, 5610
23 M2 - b-mercaptoeth-
anol, and antibiotics) and restimulated with each of the peptide
pools (2.5 mg/ml per well). An individual 9mer peptide represent-
ing the immunodominant H5N1 H05-HA (IYSTVASSL, con-
served influenza A viruses) epitope was also evaluated, along with
negative controls PR8-NP (TYQRTRALV, A/PuertoRico/8/34
(H1N1) nucleoprotein) and ZGP (TELRTFSI, Zaire Ebolavirus
glycoprotein). ELISPOT-IFNc plates were incubated at 37uC
overnight (18–20 hours) and washed the following day according
to the manufacturer’s instructions. AEC Substrate Set (BD
Biosciences) was used to develop spots formed by interferon
gamma secreting cells. Spots were visualized and counted using an
ELISPOT plate reader (AID ELISPOT reader, Cell Technology,
Colombia, Maryland).
Flow cytometric analysis
Splenocytes obtained on day 10 post-vaccination, plated at
2610
6 cells/well, were restimulated with 9mer H05-HA, PR8-NP,
or 8mer ZGP individual peptides in DMEM (supplemented with
10% FBS, L-glutamine, NaPyr, HEPES, non-essential amino
acids, 5610
23 M b-mercaptoethanol, and antibiotics), IL2, and
GolgiStop (Brefeldin A, BD Biosciences). Cells were stimulated for
5 hours and stained with anti-mouse CD8-FITC (fluorescein
isothiocyanate) at 4uC for 30 minutes. BD Cytofix and permwash
protocol was used to fix and permeabilized cells according to the
manufacturer instructions. The following day, cells were stained
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All samples were read on the LSRII Flow cytometer (BD
Biosciences). Data was analyzed using BD FACSDiva 6.0.1
software (BD Biosciences).
Antibody Detection
Serum for the detection of HA specific antibodies by neutralization
or hemagglutination inhibition assays was collected from each mouse
following immunization, as previously described [16,38]. Briefly, all
samples were treated with receptor-destroying enzyme (RDE, 1:3
ratio, Accurate Chemical) overnight at 37uC and inactivated the
following day for 45 minutes at 56uC. Starting with a 1:10 dilution,
two-fold serial dilutions of serum were done in a 96-well round-
bottom microtiter plate in virus diluent (MEM, 0.3% BSA, and
antibiotics), mixed with 100 pfu/well of homologous A/Hanoi/
30408/2005 virus and incubated at 37uC for 60 minutes. For
hemagglutination inhibition (HI) assays, two-fold serial dilutions of
each sample were performed in phosphate buffered saline (PBS) and
50 ml/well was added to a 96-well V-bottom microtiter plate. Four
hemagglutinating doses of homologous A/Hanoi/30408/2005 were
added to each well and the plates were incubated at room
temperature for one hour. Horse red blood cells (0.5% erythrocytes
in 0.85% saline) were added to each well and incubated for 60
minutes. Hemagglutination titer was determined as the reciprocal of
the highest dilution where red blood cells did not agglutinate. For
neutralization assays, the serum/virus mixture was added onto
subconfluent MDCK cells in a 96-well flat-bottom microtiter plate
and incubated for 5–10 minutes at room temperature. Virus diluent
supplemented with 3.0 mg/ml TPCK-trypsin was added into each
well (100 ml/well) and incubated at 37uC, 5% CO2, for 48 hours.
CellsweremonitoredforthepresenceorabsenceofCPEusingalight
microscope. The highest serum dilution which did not exhibit CPE
was scored as positive for neutralizing antibody and titers were
reported as the reciprocal of the dilution. All infectious in vitro work
was performed in the high containment laboratory of NML/PHAC.
An enzyme-linked immunosorbant assay (ELISA) was per-
formed to evaluate total IgG antibodies present in serum at 25
days and 1 year following vaccination. 96-well plates (NUNC)
were coated with 1 ug/ml H5 HA antigen, overnight at 4uC. The
following day, serial tenfold dilutions of serum were added to the
plates and incubated for 60 minutes at room temperature.
Following three washes, a goat anti-mouse conjugated to HRP
was applied as the secondary antibody for 45 minutes. After an
additional three washes, a 3,39,5,59-tetramethylbenzidine (TMB)
solution was added to react with the HRP conjugate and
incubated in the dark for 20 minutes. The reaction was stopped
using sulphuric acid solution. The absorbance was detected at
450 nm (OD450). The endpoint cut-off (A450=0.100) was
determined as the last serum dilution which was greater than
two times the optical density of the negative control. Endpoint
titres were reported as the reciprocal of the first serum dilution that
was higher than the cut-off.
Rapid vaccination regimen and detection of viral load
Groups of 15 BALB/c mice were vaccinated with a 10
10 vp/
mouse dose of PAV3-HA or AdHu5-HA 5, 8, or 10 days prior to
challenge with 100LD50 of H5N1-H05 virus. Nine animals were
monitored for survival and lung tissue and blood were harvested
from the remaining 6 mice three days post-infection. Virus load
was determined by the tissue culture infectious dose which will
result in cytopathic effects (CPE) of fifty percent of cell culture
(TCID50). TCID50 was performed by added serial dilutions of
homogenized lung tissue onto MDCK cells and monitoring the
presence of CPE after 48 hours. The TCID50 titre was calculated
using the Reed & Muench method [39] and normalized per gram
of lung tissue.
Graphs and Statistical analysis
All graphs were generated using GraphPad Prism 5.0 and data
were analyzed for statistical difference by performing unpaired t
test, or one-way analysis of variance (ANOVA) when appropriate.
The differences in the mean or raw values among treatment
groups were considered significant when p,0.05.
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